Explore more publications!
Djibouti Health Journal
Submit Press Release

Djibouti Health Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Djibouti Health Journal.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on October 24, 2025

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
October 24, 2025

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio

Indeterminate GlobeNewswire
Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin
October 24, 2025

Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin

Indeterminate GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
October 24, 2025

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases

Indeterminate GlobeNewswire
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
October 24, 2025

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

Indeterminate GlobeNewswire
ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET
October 24, 2025

ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET

Indeterminate GlobeNewswire
New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
October 24, 2025

New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

Indeterminate GlobeNewswire
Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production
October 24, 2025

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production

Indeterminate GlobeNewswire
Polpharma Group Announces Leadership Transition – Sebastian Szymanek appointed as its new President
October 24, 2025

Polpharma Group Announces Leadership Transition – Sebastian Szymanek appointed as its new President

Indeterminate GlobeNewswire
Avextra Supports Phase II Clinical Trial in Italy on Cannabis-based medicines for Neurodegenerative Diseases
October 24, 2025

Avextra Supports Phase II Clinical Trial in Italy on Cannabis-based medicines for Neurodegenerative Diseases

Indeterminate GlobeNewswire
Avextra supporta in Italia uno studio clinico di fase II sulla cannabis terapeutica nelle malattie neurodegenerative
October 24, 2025

Avextra supporta in Italia uno studio clinico di fase II sulla cannabis terapeutica nelle malattie neurodegenerative

Indeterminate GlobeNewswire
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control
October 24, 2025

NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control

Indeterminate GlobeNewswire
NANOBIOTIX annonce des mises à jour sur le programme clinique de JNJ-1900 (NBTXR3) à la suite du transfert de sponsorship et du contrôle opérationnel de l’essai de Phase 3 en cours dans le cancer de la tête et du cou
October 24, 2025

NANOBIOTIX annonce des mises à jour sur le programme clinique de JNJ-1900 (NBTXR3) à la suite du transfert de sponsorship et du contrôle opérationnel de l’essai de Phase 3 en cours dans le cancer de la tête et du cou

Indeterminate GlobeNewswire
Press release: Q3: continued sales and earnings progress
October 24, 2025

Press release: Q3: continued sales and earnings progress

Indeterminate GlobeNewswire
Communiqué de presse : T3 : croissance continue du chiffre d’affaires et du bénéfice
October 24, 2025

Communiqué de presse : T3 : croissance continue du chiffre d’affaires et du bénéfice

Indeterminate GlobeNewswire
ONWARD Medical Successfully Raises Over EUR 50 Million in Capital Increase
October 24, 2025

ONWARD Medical Successfully Raises Over EUR 50 Million in Capital Increase

Indeterminate GlobeNewswire

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions